Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TRACON Pharmaceuticals, Inc.
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
July 01, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 07, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Reverse Stock Split
April 08, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
April 03, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
March 05, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
February 28, 2024
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
December 20, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
November 20, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
October 31, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
September 18, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 05, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
August 02, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
July 11, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
June 20, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
June 16, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
June 15, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 30, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
May 03, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
April 25, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 08, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
February 28, 2023
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
December 27, 2022
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
December 14, 2022
From
TRACON Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TCON
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.